FOLH1 and prostate cancer: Considering that target volume delineation is a `condition sine qua non ́ for high-precision radiotherapy, the introduction of FDG-PET in lung cancer [64], amino acids –PET in brain tumors [65, 66] or PSMA-PET/CT in prostate cancer [67, 68] significantly improved the accuracy of treatment delivery and consequently the clinical outcome [64, 65, 68, 69].